Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Add To Watchlist

Recent & Breaking News (GREY:ADXS)

Advaxis Provides Additional Information on Clinical Hold

GlobeNewswire November 2, 2015

Advaxis Launches MINE(TM) Collaboration

GlobeNewswire October 27, 2015

Advaxis's Cancer Immunotherapies to be Featured in Three Poster Presentations at the 2015 SITC Annual Meeting

GlobeNewswire October 13, 2015

Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac

GlobeNewswire October 6, 2015

Healthcare Sector Stocks under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences and Cytori Therapeutics

PR Newswire September 29, 2015

First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors

GlobeNewswire September 28, 2015

Advaxis's Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival in Patients With Persistent/Recurrent Metastatic Cervical Cancer

GlobeNewswire September 17, 2015

FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac (ADXS-HPV) in HPV-Associated Head and Neck Cancer

GlobeNewswire September 14, 2015

Advaxis Accepts Medical Visionary Award From the Farrah Fawcett Foundation for Collaborative Research in HPV-Associated Anal Cancer

GlobeNewswire September 10, 2015

Advaxis to Present at the 2015 Wells Fargo Securities Healthcare Conference

GlobeNewswire September 2, 2015

Investor Alert: Investigation of Advaxis Announced by Holzer & Holzer, LLC

Business Wire September 1, 2015

Phase 2 Study of Advaxis's Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting

GlobeNewswire August 31, 2015

Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management

GlobeNewswire August 26, 2015

Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management

Marketwired August 26, 2015

Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination With Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers

GlobeNewswire August 20, 2015

Advaxis Appoints Tom Ridge, America's First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors

GlobeNewswire August 13, 2015

Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation

GlobeNewswire August 5, 2015

The First Half of 2015 Was a Huge Win for Biotech Investors: Here Are the Top Picks of the Top Stock Pickers for Q3 & Q4

Accesswire July 30, 2015

The First Half of 2015 Was a Huge Win for Biotech Investors: Here Are the Top Picks of the Top Stock Pickers for Q3 & Q4

Accesswire July 30, 2015

Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015

GlobeNewswire July 29, 2015